Literature DB >> 2902493

Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor.

C R Edwards1, P M Stewart, D Burt, L Brett, M A McIntyre, W S Sutanto, E R de Kloet, C Monder.   

Abstract

In vitro the mineralocorticoid receptor is non-specific and does not distinguish between aldosterone and cortisol. In vivo certain tissues with this receptor are aldosterone selective (eg, kidney and parotid) whereas others with the same receptor are not (eg, hippocampus and heart). Experiments in rats showed that 11 beta-hydroxysteroid dehydrogenase (which converts cortisol to cortisone in man and corticosterone to 11-dehydrocorticosterone in the rat) was much more highly concentrated in aldosterone-selective tissues than in non-selective tissues. The localisation in the selective tissues was such that the enzyme could act as a paracrine or possibly an autocrine mechanism protecting the receptor from exposure to corticosterone. Autoradiographic studies showed that protection is lost when the enzyme is inhibited; 3H-corticosterone and 3H-aldosterone were bound to similar sites. These findings seem to explain why sodium retention, hypokalaemia, and hypertension develop in subjects with congenital deficiency of 11 beta-OHSD and those in whom the enzyme has been inhibited by liquorice.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2902493     DOI: 10.1016/s0140-6736(88)90742-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  140 in total

Review 1.  Apparent mineralocorticoid excess syndromes.

Authors:  M Shimojo; P M Stewart
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

2.  Lack of tissue glucocorticoid reactivation in 11beta -hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments.

Authors:  J L Yau; J Noble; C J Kenyon; C Hibberd; Y Kotelevtsev; J J Mullins; J R Seckl
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 3.  The role of aldosterone in the metabolic syndrome.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

Review 4.  Genetics of the kidney and hypertension.

Authors:  Bracie Watson
Journal:  Curr Hypertens Rep       Date:  2003-06       Impact factor: 5.369

5.  Evidence for cortisol as the mineralocorticoid in the syndrome of apparent mineralocorticoid excess.

Authors:  R Tedde; A Pala; A Melis; S Ulick
Journal:  J Endocrinol Invest       Date:  1992-06       Impact factor: 4.256

6.  Effect of licorice on the reduction of body fat mass in healthy subjects.

Authors:  D Armanini; C B De Palo; M J Mattarello; P Spinella; M Zaccaria; A Ermolao; M Palermo; C Fiore; P Sartorato; F Francini-Pesenti; I Karbowiak
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

Review 7.  Mechanisms of hypertension: the expanding role of aldosterone.

Authors:  E Marie Freel; John M C Connell
Journal:  J Am Soc Nephrol       Date:  2004-08       Impact factor: 10.121

Review 8.  Endogenous Glucocorticoids and Bone.

Authors:  Hong Zhou; Mark S Cooper; Markus J Seibel
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

9.  Type II 11beta-hydroxysteroid dehydrogenase expression in human colonic epithelial cells of inflammatory bowel disease.

Authors:  K I Takahashi; K Fukushima; H Sasano; I Sasaki; S Matsuno; Z S Krozowski; H Nagura
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

Review 10.  Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.

Authors:  Patrick W F Hadoke; Javaid Iqbal; Brian R Walker
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.